These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 39272208)

  • 1. A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.
    Omar M; Harrell JC; Tamimi R; Marchionni L; Erdogan C; Nakshatri H; Ince TA
    Breast Cancer Res; 2024 Sep; 26(1):132. PubMed ID: 39272208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
    Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Liu D
    Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
    Liu D
    Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
    Kensler KH; Poole EM; Heng YJ; Collins LC; Glass B; Beck AH; Hazra A; Rosner BA; Eliassen AH; Hankinson SE; Winer EP; Brown M; Tamimi RM
    J Natl Cancer Inst; 2019 Jul; 111(7):700-708. PubMed ID: 30445651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer.
    Kim JY; Park K; Lee E; Jung HH; Ahn JS; Im YH; Park WY; Park YH
    Oncotarget; 2017 Jan; 8(5):8693-8706. PubMed ID: 28060723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
    Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
    Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
    Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
    PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
    Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
    BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
    Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.
    Martin KJ; Patrick DR; Bissell MJ; Fournier MV
    PLoS One; 2008 Aug; 3(8):e2994. PubMed ID: 18714348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
    Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
    Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
    BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D; Zhou K
    Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
    Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
    BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
    Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
    Buechler SA; Gökmen-Polar Y; Badve SS
    Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.